Calamos Wealth Management LLC Has $3.41 Million Stock Holdings in AbbVie Inc. $ABBV

Calamos Wealth Management LLC increased its position in AbbVie Inc. (NYSE:ABBV) by 74.7% during the third quarter, Holdings Channel reports. The firm owned 14,729 shares of the company’s stock after buying an additional 6,298 shares during the quarter. Calamos Wealth Management LLC’s holdings in AbbVie were worth $3,410,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABBV. Marshall & Sullivan Inc. WA acquired a new stake in shares of AbbVie in the second quarter valued at approximately $25,000. Evolution Wealth Management Inc. acquired a new stake in AbbVie during the 2nd quarter valued at $26,000. Spurstone Advisory Services LLC bought a new position in AbbVie during the second quarter worth $28,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie in the second quarter valued at $36,000. Finally, Delos Wealth Advisors LLC bought a new position in shares of AbbVie in the second quarter valued at about $39,000. Institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and increased their target price for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Finally, Wells Fargo & Company upped their price objective on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Price Performance

AbbVie stock opened at $229.63 on Wednesday. The firm has a market cap of $405.84 billion, a PE ratio of 173.96, a price-to-earnings-growth ratio of 1.31 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The stock’s fifty day moving average price is $226.67 and its two-hundred day moving average price is $213.27. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the company posted $3.00 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.